BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models

被引：0
|
作者：
Li, Zhuo
Qu, Liang
Chen, Xin
Xue, Liu
Li, Jie
Liu, Qi
Sun, Jian
Sun, Hanzi
Chen, Yun
Xie, Yuanyuan
Wang, Wanyi
Zhu, Lin
Wang, Penghao
Zhou, Xiaosui
Hou, Hongjia
Chen, Jie
Liu, Xinyi
Zhang, Yilu
Liu, Ning
Liang, Xinyi
Zhang, Shuo
Tang, Xiaoyan
Song, Jing
Zhang, Tong
Song, Xiaomin
Liu, Xuesong
Li, Kang
Huang, Chichi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2371
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2371
引用
收藏
页数：2
相关论文
共 6 条
  • [1] ROR1 targeted 4-1BB costimulatory bispecific antibody, ABL102, exhibits potent in vitro and vivo antitumor activity and superior safety profile
    Lee, Yangsoon
    Park, Kyeong-Su
    Son, Wonjun
    Kim, Sora
    Youn, Hyunseong
    Yoo, Jiseon
    Lee, Hanbyul
    Won, Jonghwa
    CANCER RESEARCH, 2023, 83 (07)
  • [2] A novel TIGIT and 4-1BB bispecific antibody, ABL112, exhibits potent in vitro and in vivo antitumor activity through dual immune modulation
    Son, Wonjun
    Lee, Yangsoon
    Park, Yelim
    Won, Jonghwa
    CANCER RESEARCH, 2024, 84 (06)
  • [3] YH32364 (ABL104), A NOVEL EGFR/4-1BB BISPECIFIC ANTIBODY EXHIBITS POTENT ANTITUMOR EFFICACY WITH AN EXCELLENT SAFETY PROFILE
    Lee, Eunjung
    Chung, Hyejin
    Lee, Yangsoon
    Park, Young Bong
    Lee, Eun-Jung
    Koo, Hyunmo
    Ju, Mikyeong
    Park, Ju Young
    Ahn, Sujin
    Kim, Junhwan
    Park, Kyeongsu
    Son, Wonjun
    Eom, Jaehyun
    Lee, Hanbyul
    Jung, Jaeho
    Won, Jonghwa
    Oh, Se-Woong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1100 - A1100
  • [4] HBM7008, A FIRST-IN-CLASS BISPECIFIC ANTIBODY TARGETING BOTH B7-H4 AND 4-1BB, EXHIBITS ROBUST ANTI-TUMOR IMMUNITY AND LOW TOXICITY THROUGH B7-H4-DIRECTED 4-1BB ACTIVATION
    Huang, Bing
    Du, Fangfang
    Lv, Xiaocheng
    Zhao, Jianxun
    Chen, Fei
    Lu, Zailian
    Zhang, Yang
    Chen, Victor
    Gan, Xin
    Zhao, Jiuqiao
    He, Yun
    Wu, Xiaodong
    Rong, Yiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1099 - A1099
  • [5] First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors
    Desai, Jayesh
    Frentzas, Sophia
    Fakih, Marwan
    Ameratunga, Malaka
    O'Neill, Siobhan
    Pelster, Meredith
    Stein, Brian N.
    Body, Amy
    Li, Bai
    Strauss, Ross M.
    Zhao, Yating
    Dong, Gaohong
    Cecchini, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 123 - 123
  • [6] BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity
    Han, Zhenyan
    Shang, Chengzhang
    Zhang, Yifu
    An, Gao
    Guo, Chaoshe
    An, W. Frank
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
1